Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 8/20 | 0.61 |
| ▸ | AKR1C2 | P52895 | 8/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.61 |
| ▸ | CDC42 | P60953 | 1/20 | 0.61 |
| ▸ | RAC1 | P63000 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.61 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.43 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15506110 | 1.00 | AKR1C3 (0.61) | AKR1C3AKR1C2PTGS2PTGS1CDC42 | |
| SCHEMBL15506199 | 1.00 | AKR1C3 (0.61) | AKR1C3AKR1C2PTGS2PTGS1CDC42 | |
| SCHEMBL17694468 | 0.89 | AKR1C3 (0.54) | AKR1C3AKR1C2PTGS2PTGS1CDC42 | |
| SCHEMBL17694473 | 0.89 | AKR1C3 (0.54) | AKR1C3AKR1C2PTGS2PTGS1CDC42 | |
| SCHEMBL17694465 | 0.89 | AKR1C3 (0.54) | AKR1C3AKR1C2PTGS2PTGS1CDC42 | |
| SCHEMBL23198285 | 0.89 | AKR1C3 (0.54) | AKR1C3AKR1C2PTGS2PTGS1CDC42 | |
| SCHEMBL24094555 | 0.88 | PTGS2 (0.52) | AKR1C3AKR1C2PTGS2PTGS1CDC42 | |
| SCHEMBL14605692 | 0.87 | PTGS1 (0.69) | AKR1C3AKR1C2PTGS2PTGS1CDC42 | |
| SCHEMBL27634481 | 0.85 | KMT2A (0.48) | AKR1C3AKR1C2PTGS2PTGS1CDC42 | |
| SCHEMBL586419 | 0.83 | AKR1C3 (0.54) | AKR1C3AKR1C2PTGS2PTGS1CDC42 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4444708-B1 | MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER (US) | 2025-07-30 | — | — | EP | disclosed |
| US-20250129048-A1 | MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2025-04-24 | — | — | US | disclosed |
| US-20240351966-A1 | CLASS OF ALKYLPHENOL COMPOUNDS AND PREPARATION METHOD THEREFOR | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2024-10-24 | — | — | US | disclosed |
| US-11964956-B2 | Cannabinergic compounds and uses thereof | NORTHEASTERN UNIVERSITY (US) | 2024-04-23 | — | — | US | disclosed |
| EP-4353706-A1 | CLASS OF ALKYLPHENOL COMPOUNDS AND PREPARATION METHOD THEREFOR | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2024-04-17 | — | — | EP | disclosed |
| CN-115322077-B | Alkylphenol compounds and preparation method thereof | 中国科学院上海药物研究所 | 2024-03-15 | — | — | CN | disclosed |
| WO-2023105387-A1 | MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| CN-115872930-A | N-substituted 3,4-dihydroisoquinoline-1 (2H) -ketone derivative, composition thereof and application thereof in medicines | 贵州医科大学 | 2023-03-31 | — | — | CN | disclosed |
| WO-2022237852-A1 | CLASS OF ALKYLPHENOL COMPOUNDS AND PREPARATION METHOD THEREFOR | 中国科学院上海药物研究所 | 2022-11-17 | — | — | WO | disclosed |
| CN-115322077-A | Alkylphenol compounds and preparation method thereof | 中国科学院上海药物研究所 | 2022-11-11 | — | — | CN | disclosed |
| US-8106233-B2 | Applying di-2-ethylhexyl 4-hydroxy-3,5-dimethoxy-benzylmalonate; protective action against UV rays, oxidative stress on body cells, counters skin ageing | MERCK PATENT GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20080171004-A1 | Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives | MERCK PATENT GMBH (DE) | 2008-07-17 | — | — | US | disclosed |
| US-20080152603-A1 | Antioxidants | SUSONITY Commercial GmbH (DE) | 2008-06-26 | — | — | US | disclosed |
| CN-101203278-A | Ultraviolet protection | MERCK PATENT GMBH (DE) | 2008-06-18 | — | — | CN | disclosed |
| CN-101163659-A | Antioxidants | MERCK PATENT GMBH (DE) | 2008-04-16 | — | — | CN | disclosed |
| EP-1871339-A1 | UV PROTECTION | Merck Patent GmbH (DE) | 2008-01-02 | — | — | EP | disclosed |
| EP-1871735-A1 | ANTIOXIDANTS | Merck Patent GmbH (DE) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006111233-A1 | ANTIOXIDANTS | MERCK PATENT GMBH (DE) | 2006-10-26 | — | — | WO | disclosed |
| WO-2006111234-A1 | UV PROTECTION | MERCK PATENT GMBH (DE) | 2006-10-26 | — | — | WO | disclosed |
| WO-1995011880-A1 | SUBSTITUTED AMIDES AS TACHYKININ ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 1995-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11964956-B2 | Cannabinergic compounds and uses thereof | CNR2, CNR1, GPR18 | AKR1C3 1806/4885AKR1C2 1779/4885PTGS2 629/4885 |
| US-20080152603-A1 | Antioxidants | GPX4, GPX1, CAT | AKR1C3 289/4885AKR1C2 266/4885PTGS2 320/4885 |
| US-20080171004-A1 | Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives | HPD, HAAO, UGT1A6 | AKR1C3 733/4885AKR1C2 1012/4885PTGS2 1873/4885 |
| US-20250129048-A1 | MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | MC4R, MC3R, MC2R | AKR1C3 468/4885AKR1C2 881/4885PTGS2 4175/4885 |
| US-20240351966-A1 | CLASS OF ALKYLPHENOL COMPOUNDS AND PREPARATION METHOD THEREFOR | CYP4A11, CYP27A1, CYP4F11 | AKR1C3 207/4885AKR1C2 105/4885PTGS2 1741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.